{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:34:45Z","timestamp":1792470885569,"version":"4.5.0"},"reference-count":50,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and formulary considerations of icosapent ethyl for the treatment of high triglyceride (TG) levels.\n                    <jats:bold>Data Sources:<\/jats:bold>\n                    A literature search with keywords\n                    <jats:italic toggle=\"yes\">Vascepa, icosapent ethyl, AMR101<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">eicosapentaenoic acid<\/jats:italic>\n                    of articles up to July 2013, along with the package insert for Vascepa and current guidelines for hypertriglyceridemia.\n                    <jats:bold>Study Selection\/Data Extraction:<\/jats:bold>\n                    Two phase-III, placebo-controlled, randomized, double-blind, 12-week clinical trials were included in this review: the MARINE trial and ANCHOR study. The MARINE trial consisted of mainly overweight Caucasian men with fasting TG \u2265500 and \u22642000 mg\/dL taking 4 g\/day icosapent ethyl, 2 g\/day, or placebo. The ANCHOR study consisted of mainly overweight Caucasians with type-2 diabetes mellitus on statin therapy, with fasting TG \u2265200 and &lt;500 mg\/dL taking 4 g\/day icosapent ethyl, 2 g\/day, or placebo.\n                    <jats:bold>Data Synthesis:<\/jats:bold>\n                    The MARINE trial showed a placebo-corrected median decrease in TG of 33.1% for patients receiving 4 g\/day icosapent ethyl, with no significant change in low-density lipoprotein cholesterol (LDL-C) levels. TG was reduced by 19.7% in those taking 2 g\/day. The ANCHOR study showed a placebo-corrected decrease in TG of 21.5% with a 6.3% decrease in LDL-C for patients taking 4 g\/day icosapent ethyl as add-on to statin therapy. TG was reduced by 10.1% in those taking 2 g\/day. The main adverse effect observed was joint pain (2.3%).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Icosapent ethyl is effective in reducing TG levels without increasing LDL-C, and has efficacy similar to other TG-lowering therapies with fewer adverse effects or interactions.\n                  <\/jats:p>","DOI":"10.1177\/1060028013504079","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T13:56:59Z","timestamp":1405432619000},"page":"1517-1523","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Icosapent Ethyl for Treatment of Elevated Triglyceride Levels"],"prefix":"10.1177","volume":"47","author":[{"given":"Scott D.","family":"Nelson","sequence":"first","affiliation":[{"name":"University of Utah College of Pharmacy, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Munger","sequence":"additional","affiliation":[{"name":"University of Utah College of Pharmacy, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"1013","volume-title":"Braunwald\u2019s Heart Disease: A Textbook of Cardiovascular Medicine","author":"Genest J","unstructured":"Genest J, Libby P, Gotto A. Lipoprotein disorders and cardiovascular disease. In: Zipes D, Libby P, Bronow R, Braunwald E, eds. Braunwald\u2019s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. New York, NY: Elsevier Saunders; 2005:1013-1034.","edition":"7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70023-2"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00031-9"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc5001.100624"},{"key":"e_1_3_2_7_2","first-page":"1035","volume-title":"Braunwald\u2019s Heart Disease: A Textbook of Cardiovascular Medicine","author":"Beckman J","unstructured":"Beckman J, Libby P, Creager M. Diabetes mellitus, the metabolic syndrome, and atherosclerotic vascular disease. In: Zipes D, Libby P, Bronow R, Braunwald E, eds. Braunwald\u2019s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. New York, NY: Elsevier Saunders; 2005:1035-1046.","edition":"7"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.10.004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060963"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.013"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969080-00008"},{"key":"e_1_3_2_12_2","unstructured":"Vascepa (icosapent ethyl) [product information]. Dublin Ireland: Amarin; 2012."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/104012371002200407"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.04.015"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.05.031"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.07.001"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.018"},{"key":"e_1_3_2_18_2","unstructured":"Makrides M Neumann MA Gibson RA. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr. 1996;50:352-357. doi:http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/87934."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V10102177"},{"key":"e_1_3_2_20_2","unstructured":"Micromedex Healthcare Series [Internet database]. Updated periodically. Thomson Reuters (healthcare) Inc http:\/\/www.micromedexsolutions.com\/micromed\/"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb17343.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-3278(97)90421-X"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.17.2.279"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.07.018"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.1.259"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646389"},{"key":"e_1_3_2_27_2","first-page":"497","article-title":"Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men","volume":"47","author":"Hansen JB","year":"1993","unstructured":"Hansen JB, Olsen JO, Wilsgard L, Lyngmo V, Svensson B. Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men. Eur J Clin Nutr. 1993;47:497-507.","journal-title":"Eur J Clin Nutr"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199512010-00059"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.020"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.021"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30179-1"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30324-4"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.19.3.310"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp070061"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/862504"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-007-0121-3"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_3_2_38_2","first-page":"249","article-title":"Chylomicronemia syndrome","volume":"37","author":"Chait A","year":"1992","unstructured":"Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37:249-273.","journal-title":"Adv Intern Med"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200204000-00020"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02924164"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(21)00513-6"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01127-9"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.599"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/174182679700400511"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.12.023"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800742"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38755.366331.2F"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61239-8"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"e_1_3_2_51_2","unstructured":"Drug Topics Red Book Online. Greenwood Village CO: Truven Health Analytics; 2013."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013504079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013504079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013504079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:25Z","timestamp":1777374865000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013504079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1177\/1060028013504079"],"URL":"https:\/\/doi.org\/10.1177\/1060028013504079","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}